mibefradil has been researched along with Alloxan Diabetes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, F; Li, M; Long, M; Lu, Y; Xu, Z; Zhou, S | 1 |
| Hong, SJ; Hwang, SM; Jevtovic-Todorovic, V; Obradovic, ALj; Scarpa, J; Todorovic, SM | 1 |
| Allen, TJ; Cao, Z; Cooper, ME; Hulthén, UL | 1 |
3 other study(ies) available for mibefradil and Alloxan Diabetes
| Article | Year |
|---|---|
Mibefradil reduces blood glucose concentration in db/db mice.
Topics: Animals; Blood Glucose; Blotting, Western; Brain; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Disease Models, Animal; Eating; Hypoglycemic Agents; Immunohistochemistry; Injections, Intraperitoneal; Liver; Male; Medical Illustration; Mibefradil; Mice; Reproducibility of Results; Time Factors; Treatment Outcome | 2014 |
CaV3.2 T-type calcium channels in peripheral sensory neurons are important for mibefradil-induced reversal of hyperalgesia and allodynia in rats with painful diabetic neuropathy.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Female; Hyperalgesia; Mibefradil; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Streptozocin | 2014 |
Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action.
Topics: Actins; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Calcium Channels; Diabetes Mellitus, Experimental; Dihydropyridines; Hypertrophy; Male; Mesenteric Arteries; Mibefradil; Muscle, Smooth, Vascular; Peptidyl-Dipeptidase A; Ramipril; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 1998 |